Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom
- PMID: 23303503
- PMCID: PMC3592039
- DOI: 10.1128/JCM.02816-12
Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom
Abstract
Candida africana was previously proposed as a new species within the Candida albicans species complex, together with C. albicans and C. dubliniensis, although further phylogenetic analyses better support its status as an unusual variant within C. albicans. Here we show that C. africana can be distinguished from C. albicans and C. dubliniensis by pyrosequencing of a short region of ITS2, and we have evaluated its occurrence in clinical samples by pyrosequencing all presumptive isolates of C. albicans submitted to the Mycology Reference Laboratory over a 9-month period. The C. albicans complex constituted 826/1,839 (44.9%) of yeast isolates received over the study period and included 783 isolates of C. albicans, 28 isolates of C. dubliniensis, and 15 isolates of C. africana. In agreement with previous reports, C. africana was isolated exclusively from genital specimens, in women in the 18-to-35-year age group. Indeed, C. africana constituted 15/251 (6%) of "C. albicans" isolates from female genital specimens during the study period. C. africana isolates were germ tube positive, grew significantly more slowly than C. albicans and C. dubliniensis on conventional mycological media, could be distinguished from the other members of the C. albicans complex by appearance on chromogenic agar, and were incapable of forming chlamydospores. Here we present the detailed evaluation of epidemiological, phenotypic, and clinical features and antifungal susceptibility profiles of United Kingdom isolates of C. africana. Furthermore, we demonstrate that C. africana is significantly less pathogenic than C. albicans and C. dubliniensis in the Galleria mellonella insect systemic infection model.
Figures
References
-
- Marr KA. 2004. Invasive Candida infections: the changing epidemiology. Oncology 18(14 Suppl 13):9–14 - PubMed
-
- Nucci M, Marr KA. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521–526 - PubMed
-
- Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. 1999. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participaant Group (Europe). Diagn. Microbiol. Infect. Dis. 35:19–25 - PubMed
-
- Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 31:327–332 - PubMed
-
- Ruhnke M. 2006. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts. Curr. Drug Targets 7:495–504 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
